Antengene (HKG:6996) will establish a dedicated artificial intelligence department by increasing its investment in AI-driven drug discovery and AI-focused R&D efforts.
The initiative includes deploying DeepSeek to expedite the development of its next-generation proprietary T-cell engager (TCE) pipeline, which features a steric hindrance-masking technology.
The drugmaker plans to leverage targeted algorithms and AI-driven data mining to perform cross-database, multi-omics analyses for drug discovery and development, a Wednesday bourse filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.